Protocol needed to monitor COVID-19 disease course

Newswise — For many people who survive serious infections of the novel coronavirus, the day of discharge from the hospital is not the end of the story.

Patients with underlying conditions such as asthma or other lung problems should be checked on regularly by pulmonologists or primary-care doctors for at least six months. Some will need to be monitored for one to three years, according to a new opinion piece posted online today in The Lancet-Respiratory Medicine.

Dr. Ganesh Raghu, a UW Medicine pulmonologist and expert on interstitial lung disease and pneumonia, said his commentary outlines suggestions for survivors of COVID-19, especially patients with a moderate case requiring hospitalization. He hopes hospitals and clinics will adopt the practice of regular check-ins with vulnerable patients.

“This is the first initiative to attempt to bring the pulmonary community together and have a protocolized way to monitor the disease course and provide  standard of care,  but also might provide a foundation for research as well as clinical studies,” Raghu said. He directs the Center for  Interstitial Lung Disease at UW Medical Center – Montlake.

Follow-up is needed in a  “very structured manner because there are so many uncertainties. It is too soon to determine which patients with COVID-19 are at greatest risk for developing long-term pulmonary abnormalities” he said, “and if such symptoms will resolve, improve, or become permanent, and how the pulmonary abnormalities might be affected by therapeutics that are currently under investigation.”

Recent studies indicate that while some patients recover from their initial bouts with the virus, others continue struggle with shortness of breath and fatigue months later.

Most cases would only require six months of follow-up, Raghu proposed. People who spent time in a hospital ICU may require a year of follow-up of a year, and the most severe cases might merit checkups for three years, he said.

“These hypotheses need to be tested, which requires a systematic approach, People who have pre-existing lung disease are the ones we need to watch out for.”

Raghu proposed that attending pulmonologists collaborate with researchers to understand genetic and host-susceptibility factors of COVID-19, and encourage patients to participate in clinical studies.

“This  may help us begin to understand why some people manifest disease as mild, moderate and severe forms (and) resolve the illness quickly, and some manifest the SARS and unfortunately pass away despite aggressive supportive care, while others survive and  are left with long-term disabilities."

“If we do this proactively, we will make progress in understanding this disease,” he said.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 3327
Newswise: How to Keep Children Safe from COVID-19 this Fall
Released: 18-Sep-2020 4:15 PM EDT
How to Keep Children Safe from COVID-19 this Fall
Rush University Medical Center

With the new school year started and autumn approaching, Colleen Nash, MD, MPH, Rush University Medical Center, pediatric infectious disease specialist, answers questions parents may have about keeping children safe from COVID, social distancing in the classroom and celebrating Halloween.

Released: 18-Sep-2020 4:05 PM EDT
Claims circulating on social media stating that the common cold or flu can be mistaken for COVID-19 are misleading
Newswise

The claims rely on the faulty assumption that there is no method to distinguish COVID-19 from the common cold and the flu.

Released: 18-Sep-2020 3:35 PM EDT
After developing CRISPR test, UConn researchers validate clinical feasibility for COVID-19 testing
University of Connecticut

In March, researchers in the Department of Biomedical Engineering-- a shared department in the schools of Dental Medicine, Medicine, and Engineering--began to develop a new, low-cost, CRISPR-based diagnostic platform to detect infectious diseases, including HIV virus, the novel coronavirus (SARS-CoV-2).

Newswise:Video Embedded blowin-in-the-wind
VIDEO
Released: 18-Sep-2020 3:10 PM EDT
Blowin' in the wind
University of Utah

University of Utah chemical engineers have conducted an air flow study of the venue that the Utah Symphony performs in to determine the best ways to mitigate the spread of COVID-19 through the emissions of wind instrument players.

Newswise: holman1_toned-1-768x512.jpg
Released: 18-Sep-2020 2:50 PM EDT
Study links rising stress, depression in U.S. to pandemic-related losses, media consumption
University of California, Irvine

Irvine, Calif., Sept. 18, 2020 – Experiencing multiple stressors triggered by the COVID-19 pandemic – such as unemployment – and COVID-19-related media consumption are directly linked to rising acute stress and depressive symptoms across the U.S., according to a groundbreaking University of California, Irvine study. The report appears in Science Advances, published by the American Association for the Advancement of Science.

Newswise: 243389_web.jpg
Released: 18-Sep-2020 10:55 AM EDT
Potential new drug to mitigate SARS-CoV-2 infection consequences
University of Malaga

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Newswise: 243400_web.jpg
Released: 18-Sep-2020 10:40 AM EDT
Most homemade masks are doing a great job, even when we sneeze, study finds
University of Illinois at Urbana-Champaign

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Sep-2020 8:00 AM EDT Released to reporters: 18-Sep-2020 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Sep-2020 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Sep-2020 8:30 AM EDT
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Cancer Research Institute

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.


Showing results

110 of 3327

close
1.35124